To include your compound in the COVID-19 Resource Center, submit it here.

Eisai sales and marketing update

Eisai launched Inovelon rufinamide oral suspension in Spain for the adjunctive treatment of seizures

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE